Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
申请人:——
公开号:US20030236264A1
公开(公告)日:2003-12-25
The invention provides compounds of Formula I:
1
These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which &agr;7 is known to be involved.
[EN] BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS ET LEURS MÉTHODES D'UTILISATION
申请人:NOVARTIS AG
公开号:WO2021053495A1
公开(公告)日:2021-03-25
Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.
[EN] POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE<br/>[FR] PROMÉDICAMENTS D'OPIOÏDES À SOUS-UNITÉS MULTIPLES RÉSISTANTS AUX SURDOSES ET AUX ABUS
申请人:ELYSIUM THERAPEUTICS INC
公开号:WO2018170465A1
公开(公告)日:2018-09-20
The invention provides compositions and methods for the treatment or prevention of pain. Compositions provided are resistant to overdose and abuse. Compositions provided comprise two or more different molecules, where each molecule comprises at least one GI enzyme-labile opioid agonist releasing subunit comprising an opioid agonist that is covalently linked to at least one GI enzyme inhibitor subunit.
The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.
这项发明涉及化合物、药物组合物和用于治疗病毒感染的方法。
POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
申请人:Elysium Therapeutics, Inc.
公开号:US20170100390A1
公开(公告)日:2017-04-13
The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.